Arrowhead Pharmaceuticals and Vivo Capital Launch Joint Venture Aimed at Greater China Market Arrowhead Pharmaceuticals, a US company focused on therapies triggering the RNA interference (RNAi), and Vivo Capital, a global healthcare investment firm with offices in Palo Alto, CA, and in China, have formed a new joint venture, Visirna…..
